Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.61 |
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 2/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815937 | 0.87 | BRAF (0.68) | BRAFEGFRERBB2IGF1RCDK4 | |
| SCHEMBL1641784 | 0.85 | BRAF (0.65) | BRAFMAPK14EGFRERBB2IGF1R | |
| SCHEMBL12726671 | 0.82 | BRAF (0.68) | BRAFEGFRERBB2IGF1RMAP3K14 | |
| Trifluoroacetic Acid SCHEMBL1641078 | 0.81 | BRAF (0.64) | BRAFEGFRERBB2IGF1RMAP3K14 | |
| SCHEMBL12726658 | 0.81 | BRAF (0.63) | BRAFEGFRERBB2IGF1RMAP3K14 | |
| Trifluoroacetic Acid SCHEMBL1640355 | 0.81 | BRAF (0.61) | BRAFEGFRERBB2IGF1RMAP3K14 | |
| SCHEMBL1640365 | 0.80 | BRAF (0.64) | BRAFMAPK14EGFRERBB2IGF1R | |
| SCHEMBL12766503 | 0.80 | BRAF (0.64) | BRAFEGFRERBB2IGF1RMAP3K14 | |
| SCHEMBL1641982 | 0.80 | BRAF (0.51) | BRAFRAF1MAPK14EGFRGSK3B | |
| SCHEMBL1641799 | 0.79 | BRAF (0.59) | BRAFEGFRERBB2IGF1RCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | BRAF 151/4885RAF1 331/4885MAPK14 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.